Loading clinical trials...
Loading clinical trials...
Post-Marketing Surveillance of Safety and Effectiveness of Iclusig® Tablets in Korean Patients With CML or Ph+ ALL Under the "Risk Management Plan"
Conditions
Interventions
Ponatinib
Locations
1
South Korea
Kosin University Gaspel Hospital
Busan, South Korea
Start Date
August 7, 2018
Primary Completion Date
November 29, 2022
Completion Date
June 1, 2023
Last Updated
December 7, 2022
NCT06994676
NCT06523556
NCT06236724
NCT04195633
NCT05334069
NCT05362773
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions